Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .
Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia.
BACKGROUND Mixed hyperlipidemia is characterized by elevated low-density lipoprotein cholesterol ( LDL-C ) , triglyceride ( TG ) , and TG-rich lipoprotein levels . METHODS In a multicenter , r and omized , double-blind , placebo-controlled , parallel arm trial , eligible patients were 18 to 79 years of age , with mixed hyperlipidemia ( LDL-C 130 - 220 mg/dL , TG 150 - 500 mg/dL ) . Patients with type 2 diabetes were limited to those with LDL-C of 100 to 180 mg/dL. Patients ( N = 611 ) were r and omized in a 3:3:3:1 ratio to one of 4 treatment arms for 12 weeks : ezetimibe/simvastatin 10/20 mg ( EZE/SIMVA ) + fenofibrate 160 mg ( FENO ) , EZE/SIMVA 10/20 mg , FENO 160 mg , or placebo . The primary objective was to evaluate the LDL-C-lowering efficacy of EZE/SIMVA + FENO versus FENO monotherapy . RESULTS Low-density lipoprotein cholesterol level was significantly ( P < .05 ) reduced with EZE/SIMVA + FENO ( -45.8 % ) compared with FENO ( -15.7 % ) or placebo ( -3.5 % ) , but not when compared with EZE/SIMVA ( -47.1 % ) . High-density lipoprotein cholesterol and apolipoprotein A-I levels were significantly increased with EZE/SIMVA + FENO ( 18.7 % and 11.1 % , respectively ) treatment compared with EZE/SIMVA ( 9.3 % and 6.6 % ) or placebo ( 1.1 % and 1.6 % ) , but not when compared with FENO ( 18.2 % and 10.8 % ) . Triglyceride , non-high-density lipoprotein cholesterol , and apolipoprotein B levels were significantly reduced with EZE/SIMVA + FENO ( -50.0 % , -50.5 % , and -44.7 % , respectively ) versus all other treatments . Treatment with EZE/SIMVA + FENO was generally well tolerated with a safety profile similar to the EZE/SIMVA and FENO therapies . CONCLUSIONS Coadministration of EZE/SIMVA + FENO effectively improved the overall atherogenic lipid profile of patients with mixed hyperlipidemia . Clinical trial registry number : NCT 00093899 ( http://www . Clinical Trials.gov )
Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .